Biogen
Search results
We Are Transforming the Standard of Care and Pioneering New Markets. As the leader in RNA-targeted therapeutics for more than three decades, Ionis has focused every moment on advancing drug discovery, development, and providing hope for patients.
- About
Ionis is building an extraordinary team and culture that is...
- Investors & Media
Ionis currently has five marketed medicines and a leading...
- Our Antisense Medicines
A perpetual and efficient innovation machine. Our platform...
- About
Ionis is building an extraordinary team and culture that is driven to deliver transformational medicines that pioneer new markets or fundamentally change the standard of care.
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics.
Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing.
A perpetual and efficient innovation machine. Our platform technology has served as a springboard for drug discovery and realized hope for patients with unmet needs. Our broad, diverse pipeline has more than 40 first-in-class and/or best-in-class medicines designed to treat a broad range of diseases. Review our pipeline »
Jun 25, 2024 · Ionis is planning additional regulatory filings for the treatment of FCS in the European Union this year. In addition to FCS, Ionis is evaluating olezarsen for the treatment of severe hypertriglyceridemia (sHTG) in three Phase 3 clinical trials – CORE, CORE2 and ESSENCE, all three of which completed enrollment in the first half of 2024.
Find the latest Ionis Pharmaceuticals, Inc. (IONS) stock quote, history, news and other vital information to help you with your stock trading and investing.
